Significant reductions in weight and comorbidities are seen 10+ years after surgery<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Oct. 11, 2022 (HealthDay News) — Significant and sustained reductions in weight and comorbidities are seen more than a decade after metabolic and bariatric surgery (MBS) in adolescent patients, according to a study published in the October issue of the Journal of the American College of Surgeons<\/em>.<\/p>\n Nestor de la Cruz-Mu \u00b1oz, M.D., from University of Miami Miller School of Medicine, and colleagues examined body weight, comorbidity status, social\/physical function status, and long-term complications 10 to 18 years after metabolic and bariatric surgery. The analysis included 96 patients who completed surgery at 21 years of age or younger in a tertiary academic center between 2002 and 2010.<\/p>\n The researchers found that at follow-up (mean, 14.2 years), postoperative (90.6 percent Roux-en-Y gastric bypass [RYGB] and 8.3 percent laparoscopic adjustable gastric banding [LAGB]) mean total body weight decreased by 31.3 percent (32.0 percent for RYGB and 22.5 percent for LAGB). One hundred percent remission was reported among patients with pre-MBS hyperlipidemia (14.6 percent), asthma (10.4 percent), and diabetes\/hyperglycemia (5.2 percent). Additionally, pre\u00e2\u0080\u0093post decreases were seen for hypertension, sleep apnea, gastroesophageal reflux disease, anxiety, and depression.<\/p>\n “These findings have important implications for adolescents who may be considering MBS for weight reduction and overall health improvements that extend into adulthood,” the authors write.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n